BioRestorative Therapies, Inc. (NASDAQ: BRTX) priced a public offering of 14,285,715 shares of common stock (or pre‑funded warrants) and an equal number of warrants to purchase shares at an exercise price of $0.35 per share. The combined offering price is $0.35 per share, and the transaction is expected to close on or about February 13, 2026.
The company will use the net proceeds to fund clinical trials for its lead candidate BRTX‑100, advance pre‑clinical research for the ThermoStem program, develop its commercial biocosmeuticals platform, and support general corporate purposes and working capital needs.
Investors reacted negatively to the announcement, citing concerns that the offering price is substantially below recent trading levels and that the issuance of new shares and warrants will dilute existing shareholders’ equity.
BRTX‑100 enrollment for its Phase 2 trial was completed on February 10, 2026, and the company received a positive Type B meeting from the FDA regarding an accelerated BLA pathway. The ThermoStem program has progressed with a Japanese patent allowance in October 2025, positioning it as a potential competitor to GLP‑1 drugs in the obesity market. Despite these milestones, the company’s operating and net margins remain highly negative, underscoring the need for external financing.
The Form S‑1 registration statement was declared effective by the SEC on February 11, 2026, and Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering. The transaction will add 14,285,715 shares to the outstanding capital structure and is expected to close on or about February 13, 2026.
The dilution from the new shares and warrants, combined with the low offering price, raises questions about the company’s ability to raise capital at higher valuations. The proceeds will support critical clinical and pre‑clinical programs, but the transaction highlights the ongoing need for capital to sustain operations and advance the company’s pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.